Stocks · News reference

BrainsWay Says Secondary Analysis Of Deep TMS Trial Published In Journal Of Affective Disorders Showed Suicidal Ideation Fell From 22.5% Of 89 Patients At Baseline To 6.7% At Six Weeks

Aug 27, 2026, 11:30 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 31, 2026, 12:16 PMAvi Kapoor
Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price
BWAY DE DELL GTLB HPE
BenzingaAug 31, 2026, 10:12 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $19
BWAY
BenzingaAug 13, 2026, 6:32 PMBenzinga Newsdesk
Ladenburg Thalmann Maintains Buy on BrainsWay, Raises Price Target to $18.8
Ladenburg Thalmann analyst Jeffrey Cohen maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $18 to $18.8.
BWAY